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Bacterial and viral mRNAs are often polycistronic.
Akin to alternative splicing, alternative translation of
polycistronic messages is a mechanism to generate
protein diversity and regulate gene function.
Although a few examples exist, the use of polycis-
tronic messages in mammalian cells is not widely
appreciated. Here we report an example of alterna-
tive translation as a means of regulating innate
immune signaling. MAVS, a regulator of antiviral
innate immunity, is expressed from a bicistronic
mRNA encoding a second protein, miniMAVS. This
truncated variant interferes with interferon produc-
tion induced by full-length MAVS, whereas both pro-
teins positively regulate cell death. To identify other
polycistronic messages, we carried out genome-
wide ribosomal profiling and identified a class of anti-
viral truncated variants. This study therefore reveals
the existence of a functionally important bicistronic
antiviral mRNA and suggests a widespread role for
polycistronic mRNAs in the innate immune system.
INTRODUCTION
Signal-transduction pathways are a critical part of the immune
response to control the magnitude of inflammation. Regulation
of such pathways maintains homeostasis in many cellular pro-
cesses, and a common means of generating this regulation is
through the diversification of protein form and function. From a
single genetic locus, this diversification can be achieved through
alternative splicing and/or translation, resulting in the production
of multiple proteins with distinct functions. This is a highly effec-
tive way of altering protein activities because it offers a mecha-
nism for removing or adding functional domains.
In eukaryotes, protein diversification can be generated during
mRNA processing, and examples of this form of regulation
include the gene RIG-I (Gack et al., 2008), a master regulator
of antiviral innate immunity (Yoneyama et al., 2004). RIG-I is800 Cell 156, 800–811, February 13, 2014 ª2014 Elsevier Inc.the founding member of the RIG-I like receptor (RLR) family,
which functions to detect viruses containing RNA (and in some
instances DNA) genomes in the cytosol of infected cells (Nakhaei
et al., 2009). Upon binding to viral RNA, RIG-I engages an
adaptor protein calledMAVS to induce the expression of antiviral
factors such as type I interferon (IFN) and IFN-stimulated genes
(ISGs) (Sun et al., 2006). RIG-I encodes a full-length transcript
controlling this proinflammatory response as well as a truncated
splice variant that limits the signaling potential of its counterpart
(Gack et al., 2008). The Toll-like receptor (TLR) adaptor proteins
MyD88 and TRAM offer additional examples of this phenome-
non; both of these genes encode splice variants that can differ-
entially regulate an inflammatory response (Burns et al., 2003;
Palsson-McDermott et al., 2009). Thus, alternative splicing is
an established means of generating protein diversity and con-
trolling the activity of immune-signaling pathways.
An alternative method to generate protein diversity is through
the process of translation, whereby distinct proteins can be
created from a single mRNA. Although the alternative translation
of polycistronic messages is generally considered to be virus
or prokaryote specific, recent genome-wide ribosomal profile
studies suggest that polycistronic mRNAs may be more com-
mon in eukaryotes than previously appreciated (Guttman et al.,
2013; Ingolia et al., 2011). For example, embryonic stem cells
contain thousands of mRNAs that are predicted to have more
than one translational start site (Ingolia et al., 2011). However,
whether these newly annotated start sites actually produce pro-
tein products that are functional and stable remains an unan-
swered question. In fact, there are very few bona fide examples
in mammalian cells of more than one protein being produced by
a single mRNA (Burkart et al., 2012; Cocka and Bates, 2012; De-
scombes and Schibler, 1991; Shinohara et al., 2008; Yin et al.,
2002), and no example of this type of gene regulation exists in
the common signaling pathways of the innate immune system.
In this report, we identify two regulators of antiviral innate
immunity that are translated from the same bicistronic message.
The transcript encoding the RLR adaptor protein MAVS pro-
duces the well-characterized full-length (FL) MAVS adaptor
and a truncated variant we refer to as miniMAVS. These proteins
are functionally distinct and uniquely regulate antiviral signal
transduction. Moreover, genome-wide ribosomal profiling in
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Figure 1. miniMAVS Is Expressed from a
Second Translational Start Site
(A) Lysates from several different human cell lines
were separated by SDS-PAGE, and endogenous
MAVS expression was detected with a MAVS
antibody.
(B) In vitro transcription and translation of the
MAVS CDS were compared with 293T cell lysates
with an anti-MAVS antibody.
(C) Schematic of MAVS with predicted translation
products FL MAVS and miniMAVS from the start
sites corresponding to Met1 and Met142.
(D and E) Point mutations of translational start sites
at Met1 and Met142 were made in theMAVS CDS
and expressed in vitro (D) and in vivo (E) from
MAVS-deficient MEFs. The translation products
were detected by immunoblot with a MAVS
antibody.
See also Figure S1.human monocytes identified additional innate immune regula-
tors that contain multiple translation start sites. This study high-
lights how protein diversification in the innate immune system
can be achieved at the level of translation and suggests that
eukaryotic polycistronic messages may have widespread roles
in controlling immunity.
RESULTS
Identification of miniMAVS, a Truncated Variant of FL
MAVS
One of the original reports identifying the MAVS gene
described the generation of a MAVS-specific antibody raised
against a peptide consisting of amino acids 131–291 (Seth
et al., 2005). This antibody detected two MAVS proteins with
apparent molecular weights of 50 and 72 kDa. It was specu-
lated that the 50 kDa variant represented a degradation prod-
uct or processed version of the 72 kDa full-length variant FL
MAVS (Seth et al., 2005). To date, all antiviral activities of the
MAVS gene have been attributed to FL MAVS (Kawai et al.,
2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005).
The origin and function of the smaller protein, miniMAVS,
have yet to be defined. These two MAVS proteins can be de-
tected in various human cell lines, indicating that the expres-
sion of both MAVS proteins is ubiquitous (Figure 1A). We
considered the possibility that alternative mRNA splicing could
explain the existence of a second MAVS variant. However,
although several MAVS splice variants have been identifiedCell 156, 800–811,(Lad et al., 2008), none correspond to
the correct size of miniMAVS (50 kDa)
(data not shown). Additionally, both FL
MAVS and miniMAVS were expressed
from the MAVS coding region (CDS) by
in vitro transcription and translation (Fig-
ure 1B). These data indicate that the two
MAVS variants are generated from a
single transcript and are therefore not
generated by differential mRNA splicing.The presence of a methionine at amino acid 142 of the MAVS
CDS suggested that miniMAVS expression is the result of trans-
lation initiation at an alternative start site (Figure 1C). Consistent
with this hypothesis, initiation at this putative start codon
(Met142) would generate a protein that corresponds to the
molecular weight of miniMAVS (50 kDa) and shares sequence
homology with FL MAVS. To determine whether Met142 is
required for the production of miniMAVS, we mutated the corre-
sponding start sites by replacing the methionine with an alanine.
Mutation of either the methionine at position 1 or the methionine
at position 142 resulted in the respective loss of FL MAVS or
miniMAVS expression in vitro (Figure 1D). Furthermore, stable
expression of these mutant alleles in MAVS-deficient mouse
embryonic fibroblasts (MEFs) had a similar expression pattern
(Figure 1E). The putative start site corresponding to Met142 of
human MAVS is conserved among primates and other higher
mammals (Figure S1A available online). In contrast, rodent
MAVS sequences (e.g., ferret, guinea pig, mouse, rat, and squir-
rel) do not contain a corresponding Met142. Thus miniMAVS
appears to have evolved later in evolution than the MAVS protein
itself. These results suggest that the human MAVS transcript is
bicistronic and that miniMAVS is the product of a unique open
reading frame (ORF) downstream of the FL MAVS start site.
The MAVS mRNA Is Bicistronic and Can Produce Two
Distinct Proteins
The methionine mutations described above suggest that
miniMAVS expression is the result of alternative translation of aFebruary 13, 2014 ª2014 Elsevier Inc. 801
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Figure 2. MAVS Is Bicistronic, and In Vivo Ribosome Initiation Is
Detected at the FL MAVS and miniMAVS Start Sites
(A) Schematic of the HA-shift expression vector containing a frameshift
mutation and the predicted translation products ‘‘HA-shift’’ and miniMAVS.
(B) Lysates from stable MEF lines expressing the MAVS and HA-shift con-
structs were separated by SDS-PAGE, and protein expression was deter-
mined with MAVS and HA antibodies.
(C) Pattern of ribosome initiation (harringtonine treatment) and elongation on
endogenous MAVS mRNA in 293T cells.bicistronicMAVS transcript. However, the possibility also exists
that miniMAVS is created by the proteolytic cleavage of FL
MAVS, and that the methionine at position 142 is necessary for
this cleavage event. If the MAVS transcript is truly bicistronic,
then we should be able to engineer this mRNA to produce two
distinct protein products that share no amino acid homology.
To this end, a two-nucleotide insertion was introduced between
the FLMAVS andminiMAVS start sites in aMAVS construct con-
taining an N-terminal HA epitope tag (Figure 2A). This insertion
will shift the reading frame of HA-tagged FL MAVS, resulting in
an altered amino acid sequence and a truncated protein called
HA-shift. However, because the insertion is upstream of the
miniMAVS start site, the reading frame and amino acid sequence
of miniMAVS should not be affected. Although the HA-shift pro-
tein could be detected by antibodies specific for the HA epitope
tag, the shift in reading frame rendered the protein undetectable
by the MAVS antibody (Figure 2B). Interestingly, this transcript802 Cell 156, 800–811, February 13, 2014 ª2014 Elsevier Inc.still produced miniMAVS, as detected with the MAVS antibody
(Figure 2B). The expression of these two distinct proteins from
the same transcript demonstrates the bicistronic nature of the
MAVS mRNA. Additionally, the frameshift mutation rules out
the possibility that miniMAVS is generated by posttranslational
proteolysis of FL MAVS.
We next investigated the bicistronic nature of the endogenous
MAVSmRNA inside of human cells. Ribosomal profiling ofMAVS
mRNAwas performed in HEK293T cells. Ribosomal profiling is a
strategy that utilizes deep sequencing of ribosome-protected
mRNA fragments to investigate different aspects of translation
(Ingolia et al., 2011, 2012, 2013). In conjunctionwith the drug har-
ringtonine, which stalls ribosomes at initiation codons, this tech-
nique allows for the identification of functional translational start
sites on endogenous mRNAs (Ingolia et al., 2011, 2012, 2013). In
the absence of harringtonine, ribosomes were found throughout
the ORF ofMAVS, indicating active translation (Figure 2C). How-
ever, in the presence of harringtonine, ribosomes on the MAVS
mRNA were predominately stalled at the two start sites we iden-
tified that correspond to methionine 1 andMet142 of MAVS (Fig-
ure 2C). Therefore, the same translational start sites that are
required for FLMAVS andminiMAVS expression in vitro are sites
of translation initiation on the endogenous MAVS mRNA in vivo.
Taken together, these results establish that the MAVS mRNA is
bicistronic and encodes for FL MAVS and miniMAVS by alterna-
tive translation of two distinct start sites.
Cis-Acting Elements that Regulate the Translation of
miniMAVS
To further understand how the expression of FL MAVS and
miniMAVS is regulated, we characterized cis-acting elements
that control the expression of these variants. One mechanism
by which downstream ORFs are expressed from a single tran-
script involves leaky ribosomal scanning through upstream start
codons (Kozak, 2002; Somers et al., 2013). Typically, ribosomal
scanning begins at the 50 cap of a transcript, and translation is
initiated at the first optimal start site. Optimal translational start
sites depend on the nucleotide context directly surrounding a
start codon (Kozak, 1999). Leaky ribosomal scanning occurs
when the start site is suboptimal, and ribosomes fail to initiate
translation (Kozak, 2002). Under these conditions, ribosomes
will ‘‘leak’’ through the initial start site, continue scanning along
the mRNA, and initiate at a downstream start site. This mecha-
nism predicts that the expression of downstream proteins is
dependent on the translational context of upstream start sites.
If miniMAVS expression requires leaky ribosomal scanning,
then blocking ribosome scanning should decrease miniMAVS
expression. To test this, we blocked ribosomal scanning by
introducing a new start codon between the FLMAVS start codon
and the miniMAVS start codon. Initiation at this new start
codon would block scanning by translating a third protein,
‘‘midiMAVS,’’ thus preventing ribosomes from reaching the
miniMAVS start site. Introduction of a new start codon in a posi-
tion that has a naturally strong start context (L62M) suppressed
miniMAVS expression (Figure 3A, lane 2). However, artificial start
codons with weaker translational start contexts (G67M and
E80M) were leaky, allowing ribosomes to proceed and more effi-
ciently translate miniMAVS (Figure 3A, lanes 3 and 4). These
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Figure 3. Cis-Regulatory Elements of the
MAVS Transcript Control miniMAVS Ex-
pression
(A) Translational start sites of varying strengthwere
introduced at Leu62, Gly67, and Glu80 of the
MAVS CDS to block ribosomal scanning between
the FL MAVS and miniMAVS start sites. The con-
structs were expressed in vitro, and the resulting
MAVS products were detected by immunoblot
with an anti-MAVS antibody.
(B) In vitro expression of two MAVS CDS con-
structs containing a strong (Kozak) or weak (anti-
Kozak) translational context at the FL MAVS
start site.
(C) Expression of the FL MAVS and miniMAVS in
MAVS-deficient MEFs transfectedwith expression
constructs containing the endogenous 50 UTR of
MAVS or constructs with mutated start sites for
ORF1 or ORF3, 4.
(D) Schematic of the MAVS mRNA containing the
endogenous 50 UTR and highlighting the three
ORFs (red) that are out-of-frame with FL MAVS
and miniMAVS. Numbers indicate the distance (in
nucleotides) that each start site is from the FL
MAVS start site.
See also Table S1.results are consistent with the idea that miniMAVS expression
relies on leaky ribosomal scanning from the FL MAVS start site
to the miniMAVS start site.
Based on these data, the translational context of any upstream
start site, including the FL MAVS start site, could affect the
expression of miniMAVS. This possibility was addressed by
placing an artificially strong (Kozak) translational context and a
weak (anti-Kozak) translational context at the FL MAVS start
site (Kozak, 2002). A strong translational context at the FL
MAVS start site resulted in the high expression of FL MAVS
compared to that of miniMAVS, whereas a weak translational
context resulted in the lower expression of FL MAVS and high
expression of miniMAVS (Figure 3B). These results establish
the translational context surrounding the FL MAVS start site as
a cis-element that controls the expression of miniMAVS.
The above-described experiments all point to an important
role for the endogenous 50 untranslated region (UTR) of the
MAVS transcript in controlling the expression of miniMAVS, as
this region contains the natural translational context of the FL
MAVS start site. To address this directly, a MAVS expression
vector containing the endogenous 50 UTR was created. When
MAVS-deficient MEFs were transiently transfected with this vec-
tor, both FL MAVS and miniMAVS were expressed (Figure 3C,
lane 2), indicating that the endogenous context at the FL
MAVS start site is sufficient for miniMAVS expression.
Examination of all the natural start codons present within the
50 UTR and coding region upstream of miniMAVS suggested a
mechanism by which the FL MAVS start site is skipped en route
to translating miniMAVS. Three additional start codons are pre-
sent within this region, including one in the 50 UTR (ORF1) coding
for an out-of-frame upstreamORF (uORF) (Figure 3D). The trans-
lation of uORFs in 50 UTRs is emerging as a means by which
translation of downstream ORFs can be regulated (Somers
et al., 2013). For example, if initiation occurs at a uORF that over-laps with the start site of a canonical ORF, the translating ribo-
some will skip the start codon of the canonical ORF (Somers
et al., 2013). After termination of uORF translation, the ribosome
may resume scanning and reinitiate translation at downstream
ORFs. ORF1 is an overlapping uORF, predicted to initiate the
translation of a small peptide that overlapswith the coding region
of FL MAVS, terminating past its start site (Figure 3D). We pre-
dicted that translation of ORF1 might allow ribosomes to bypass
the FL MAVS start site, resume scanning, and reinitiate at the
miniMAVS start site. To test this, the start site of ORF1 was
mutated, as were the start sites for ORF3 and ORF4, which
may create small peptides within the MAVS coding region
(Figure 3D). The resulting constructs were then tested for the
expression of FL MAVS and miniMAVS in MAVS-deficient
MEFs. Interestingly, mutating the start codon of ORF1 reduced
the level of miniMAVS relative to FL MAVS, whereas mutating
ORF3 and ORF4 had a minimal effect on miniMAVS expression
(Figure 3C). These data suggest that ORF3 and ORF4 are likely
bypassed by leaky scanning, whereas translation of ORF1 allows
ribosomes to skip the FL MAVS start site and facilitate the trans-
lation of miniMAVS, likely by reinitiation. However, because FL
MAVS is expressed when ORF1 is present (Figure 3C), skipping
of the FL MAVS start site cannot occur 100% of the time. We
therefore speculated that leaky scanning might occur at the
ORF1 start site, allowing for FL MAVS translation. Consistent
with this hypothesis, the translational context at the ORF1 is sub-
optimal, suggesting a mechanism by which leaky scanning may
occur (Table S1). It should be noted, however, that we cannot
exclude the possibility that the mutation at the ORF1 start site in-
fluences the mRNA in additional ways (e.g., changes in second-
ary structure), which may contribute to altering the regulation of
translation. Overall, our collective data reveal cis-regulatory ele-
ments in the 50 UTR of theMAVS transcript that explain the rela-
tive translation efficiency of FL MAVS and miniMAVS.Cell 156, 800–811, February 13, 2014 ª2014 Elsevier Inc. 803
miniMAVS Interferes with the Signaling Function of FL
MAVS
Having established that the MAVS transcript encodes two pro-
teins, we were interested in determining the role of each protein
in the antiviral activities attributed to the MAVS gene. To study
the respective signaling functions of FL MAVS and miniMAVS,
we utilized the tools generated to characterize their expression.
First, the start-site mutations (Figures 1D and 1E) could be used
to test each variant individually for the ability to activate a given
cellular response. Second, changes in the translational context
of the FL MAVS start site could be used to manipulate the
expression ratio of FL MAVS to miniMAVS and determine how
they function in conjunction. This latter point was of interest, as
we noted a change in the ratio of FL MAVS to miniMAVS
following viral infection (Figure S2A). Whereas FL MAVS became
less abundant in infected cells over time, miniMAVS protein
levels were not affected (Figure S2A). Thus, as the infection
progressed, miniMAVS became the dominant MAVS variant in
the cell.
We began by overexpressing the MAVS start-site mutants in
293T cells and measuring the resulting production of type I
IFN. When only the FL MAVS variant (M142A) was expressed,
robust production of type I IFN was observed (Figure 4A).
Conversely, when only miniMAVS (M1A) was expressed, there
was no induction of type I IFN. In addition, a miniMAVS deletion
mutant lacking the C-terminal localization signal (M1A-500) was
not capable of inducing the production of IFN (Seth et al., 2005).
This experiment suggests that FLMAVS is sufficient to positively
regulate the production of IFN, whereas miniMAVS is not suffi-
cient to activate the pathway. However, when the two variants
were expressed in conjunction (MAVS), there was a decrease
in type I IFN production compared to FL MAVS expression alone
(Figure 4A). To corroborate these findings, the phosphorylation
of STAT1, an indicator of IFN signaling (Stark and Darnell,
2012), wasmonitored over the course of 24 hr following transfec-
tion. Compared to FL MAVS expression alone (M142A), cells
expressing both MAVS variants (MAVS) contained lower levels
of phosphorylated STAT1 over time (Figures 4A and S2B). This
difference in signaling activity between cells expressing FL
MAVS alone and cells expressing both MAVS variants was not
the result of differential expression of FL MAVS. Indeed, western
analysis indicated comparable expression of FL MAVS when ex-
pressed alone (M142A) or when expressed in conjunction with
miniMAVS (MAVS) (Figures 4A and S2B). Taken together, these
results suggest that miniMAVS antagonizes the signaling func-
tion of FL MAVS and inhibits IFN production.
To more directly test the hypothesis that miniMAVS can inhibit
the production of IFN, we used an expression construct with a
weak translational context at the FLMAVS start site. Due to leaky
scanning, this weak translational context would increase the
ratio of miniMAVS to FL MAVS in the cell, and we hypothesized
that this increase in ratio would further inhibit the production of
type I IFN. A weak translational context resulted in higher abun-
dance ofminiMAVS relative to FLMAVSwhen both variants were
expressed (MAVS, Figure 4B), as compared to the experiments
using MAVS with a strong translational context (Figure 4A).
Remarkably, when both variants were expressed in conjunction
(MAVS), the effect was a complete abrogation of IFN production804 Cell 156, 800–811, February 13, 2014 ª2014 Elsevier Inc.and STAT1 phosphorylation (Figures 4B and S2C). However,
under the same conditions, when FLMAVSwas expressed alone
(M142A), a robust production of IFN and STAT1 activation was
observed (Figures 4B and S2C). Taken together, these data
reveal miniMAVS as an inhibitor of FL MAVS signaling and that
the ratio of FL MAVS to miniMAVS determines whether an anti-
viral response will occur.
To further test miniMAVS inhibition of IFN signaling, expres-
sion constructs that more closely mimicked the natural MAVS
transcript were examined. We assessed the activation of IFN
signaling following expression from constructs containing the
endogenous 50 UTR and MAVS CDS. As described earlier,
ORF1 in the 50 UTR of the transcript can regulate the expres-
sion of miniMAVS, and when mutated, there is a decrease in
miniMAVS expression (Figure 3C). Due to this, we hypothesized
that mutating the ORF1 start site would increase IFN production.
Consistent with this idea, when compared to the wild-type (WT)
50 UTR construct, expression of the uORF1 mutant resulted in
increased STAT1 activation (Figure 4C). These data further
establish that miniMAVS can interfere with the FL MAVS IFN
response and identify uORF1 as a regulator of both the expres-
sion and function of miniMAVS.
Having established regulatory effects of FL MAVS and
miniMAVS on antiviral signaling, we predicted that differential
expression of the two proteins would also affect viral replication.
Whereas the expression of miniMAVS alone (M1A) had little
effect on the replication of vesicular stomatitis virus (VSV), FL
MAVS expression alone (M142A) dramatically reduced VSV
replication (Figure 4D). Interestingly, expression of the two pro-
teins in conjunction (MAVS, as in Figure 4B) was less effective
at limiting viral replication as compared to expression of FL
MAVS alone (Figure 4D). These data therefore establish that
miniMAVS acts to restrict the signaling functions of FL MAVS,
the physiological consequence of which is that FL MAVS is
less able to create an antiviral cellular state.
During viral infections, large aggregates of FL MAVS form that
recruit downstream enzymes to promote the expression of type I
IFNs (Hou et al., 2011). It was therefore possible that miniMAVS
restricts the signaling functions of FL MAVS by preventing the
formation of these large protein aggregates. To address this pos-
sibility, FL MAVS was expressed alone or in conjunction with
miniMAVS, and FL MAVS aggregates were detected following
sucrose gradient ultracentrifugation. For these studies, the
expression constructs containing the weak translational context
from Figure 4B were used, as under these conditions, miniMAVS
completely abrogated the production of IFN. When FL MAVS
alone (M142A) was expressed, aggregates of FL MAVS could
be detected at the bottom of the sucrose gradient (Figure 4E).
This was expected because the expression of FL MAVS results
in the production of IFN (Figure 4B), and it is thought that IFN
signaling is a result of MAVS aggregation (Hou et al., 2011). Inter-
estingly, when both FL MAVS and miniMAVS were expressed in
conjunction (MAVS), we also detected the formation of FL MAVS
aggregates (Figure 4E). This was surprising because, under
these conditions, miniMAVS completely blocks the production
of IFN (Figure 4B). These data suggest that miniMAVS cannot
block FL MAVS aggregate formation, even under conditions
where the signaling functions of FL MAVS are completely
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Figure 4. FL MAVS-Dependent IFN Production Is Inhibited by miniMAVS
(A and B) The MAVS-dependent antiviral response was measured by IFN bioassay and STAT1 phosphorylation. The MAVS CDS and translational start point
mutants were transfected into 293T cells using vectors with a strong translational context (A) as well as a weak translational context (B). FL MAVS andminiMAVS
expression is shown by MAVS immunoblot.
(C) STAT1 phosphorylation at 8 and 16 hr after the transient expression ofMAVS with the endogenous 50 UTR or uORF point mutants in 293T cells. The ratio of
STAT1 phosphorylation to FL MAVS expression was quantified by densitometry. Densitometry is from a representative image of an experiment done in triplicate.
(D) 293T cells were transfected with the MAVS constructs from (B) for 24 hr and then infected with VSV-encoding firefly luciferase. Luciferase activity was
determined 7 hr after VSV infection.
(E) Crude mitochondria (P5) isolated from 293T cells transfected withMAVS or the M142A point mutant were separated by sucrose gradient ultracentrifugation.
FL MAVS oligomers segregated to the bottom of the gradient (right) and were detected by SDS-PAGE followed by immunoblot.
(F) 293T cells were transfected with Flag-tagged miniMAVS, RIG-I, or TRAF6, and Flag-immunoprecipitates were probed for endogenous TRAF2 and TRAF6.
***p < 0.001 by ANOVA with Tukey’s multiple comparison test. Error bars represent SD. See also Figure S2.
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prevented. Consistent with the idea that miniMAVS does not in-
fluence the aggregate-forming activity of its full-length counter-
part, we found that in response to Sendai virus infections,
endogenous miniMAVS does not cosediment with FL MAVS
aggregates (Figure S2D). Thus, miniMAVS is neither a compo-
nent of FL MAVS aggregates nor does it regulate their formation.
Aggregates of FL MAVS promote antiviral signaling by recruit-
ment of the E3 ubiquitin ligases TRAF2 and TRAF6 (Liu et al.,
2013). Because miniMAVS was not capable of blocking FL
MAVS aggregation, we hypothesized that it may interfere with
signal transduction by interacting with these downstream sig-
naling proteins. To test this, we used a Flag-tagged miniMAVS
expression vector and tested Flag-immunoprecipitates for the
presence of endogenous TRAF2 and TRAF6. Both endogenous
TRAF proteins interacted specifically with Flag-miniMAVS as
compared to Flag-tagged RIG-I or a vector control (Figure 4F).
Flag-tagged TRAF6 formed amodest complex with endogenous
TRAF2. Additionally, when Flag-miniMAVS was coexpressed
with HA-TRAF6 or HA-TIRAP, TRAF6 was detected in the Flag-
immunoprecipitates, whereas the TLR adaptor TIRAP was
largely absent (Figure S2E). Taken together, these data indicate
that miniMAVS forms a complex with TRAF proteins that are
known to promote antiviral signaling and IFN production. A
possible mechanism of miniMAVS function may therefore be
proposed whereby two protein complexes exist that contain
MAVS. One complex consists of FL MAVS aggregates and
TRAF proteins and is capable of activating type I IFN expression
(Liu et al., 2013). The second complex consists of miniMAVS and
the same TRAFs (Figures 4F and S2E) yet is incapable of acti-
vating type I IFN expression. The regulation of the functional
competition between these two complexes remains an open
area of inquiry.
miniMAVS Positively Regulates Cell Death
In addition to activating antiviral gene expression,MAVScanpro-
mote cell death upon overexpression or in response to certain
viral infections (Lei et al., 2009). As with the IFN response, the
role of miniMAVS in cell death is unknown. To test whether either
MAVS variant is sufficient to activate cell death, we determined
whether overexpression of either variant was sufficient to kill
transfected 293T cells. When both variants were overexpressed
in conjunction (MAVS), there were visible signs of cell death
compared to cells transfected with a vector control (Figure 5A).
Interestingly, when miniMAVS (M1A) or FL MAVS (M142A) were
expressed alone, we also observed signs of cell death. Quantifi-
cation of the number of cells that detached from the tissue-
culture plate revealed that FL MAVS and miniMAVS induce
comparable amounts of cell death at 30 hr following transfection
(Figure 5B, left panel). However, by 48 hr, cell death induced by
FL MAVS exceeded that of miniMAVS (Figure 5B, right panel).
The increase in cell death induced by FLMAVSmay be the result
of secreted IFNs, which can positively influence cell death
(Chawla-Sarkar et al., 2003). Interestingly, a miniMAVS deletion
mutant lacking the C-terminal localization domain (M1A-500)
did not show signs of cell death compared to the vector control
(Figures 5A and 5B). Based on these data, we hypothesized
that miniMAVS may function to positively regulate cell death in
a localization-dependent, but IFN-independent manner.806 Cell 156, 800–811, February 13, 2014 ª2014 Elsevier Inc.To further investigate the induction of cell death by FL MAVS
and miniMAVS, we assessed whether they can induce two
hallmarks of this process. Programmed cell death, including
apoptosis and necroptosis, is often characterized by the frag-
mentation of genomic DNA (Green and Reed, 1998). Both
miniMAVS (M1A) and FL MAVS (M142A) induced the fragmenta-
tion of genomic DNA following expression in 293T cells (Fig-
ure 5C). In support of our visual observations of cell death, the
miniMAVS mutant (M1A-500) lacking the localization signal
was not capable of inducing DNA fragmentation. As a control,
we monitored DNA fragmentation induced by a known regulator
of cell death, the TLR adaptor TRIF (Figure 5C) (Han et al., 2004;
Ruckdeschel et al., 2004). Prior to the commitment toward cell
death and DNA fragmentation, caspases become activated
and subsequently cleave a variety of target substrates to carry
out apoptosis (Green and Kroemer, 1998). PARP is one of the
targets of these activated caspases, making detection of the
cleaved product of PARP a reliable marker for cell death. To
further investigate the induction of cell death by FL MAVS and
miniMAVS, we assessed whether they can induce PARP cleav-
age individually or in conjunction. At several time points following
the expression of both variants in conjunction (MAVS), the
cleaved product of PARP was observed (Figure 5D). Again,
TRIF was used as a positive control for cell death to monitor
PARP cleavage. In agreement with our DNA fragmentation re-
sults, PARP cleavage was detected in cells individually express-
ing either miniMAVS (M1A) or FL MAVS (M142A) but not cells
expressing the improperly localized miniMAVS mutant M1A-
500. These data indicate that unlike their antagonizing activities
toward IFN expression, FL MAVS or miniMAVS can both
promote PARP cleavage and cell death. Although the MAVS
localization domain directs this adaptor tomitochondria and per-
oxisomes (Dixit et al., 2010; Horner et al., 2011), the central role
of mitochondria in programmed cell death led us to speculate
that the death-inducing signal from MAVS probably emerges
from this organelle (Green and Kroemer, 1998). When another
mitochondrial protein (NLRX1) (Moore et al., 2008) was exam-
ined in the PARP-cleavage assay, no PARP cleavage was
observed (Figure 5D). Therefore, the observed cell-death pheno-
type is specific to FL MAVS and miniMAVS and is not a general
response to ectopic expression of another mitochondrial mem-
brane protein. Thus, in addition to their antagonistic actions in
regulating IFN expression, FL MAVS and miniMAVS can each
promote the cell-death response.
Ribosomal Profiling Predicts a Class of Bicistronic
mRNAs that Encode Regulators of Innate Immunity
MAVS can now be added to a small list of eukaryotic genes
known to produce bicistronic transcripts. However, based on
previous ribosomal profiling studies in embryonic stem cells
(Ingolia et al., 2011), there may be many more examples that
exist but have yet to be identified. To determine whether other
regulators of antiviral innate immunity encode bicistronic tran-
scripts, we carried out ribosomal profiling in U937 cells, a human
monocyte cell line. In the presence of harringtonine, we identified
14,336 start sites on 8,893 transcripts (Table S2). Many tran-
scripts present in U937 cells had more than one start site (Fig-
ures 6A and 6B). These start sites consist of a number of different
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Figure 5. miniMAVS Is Sufficient to Induce Cell Death
(A) Micrographs of 293T cells 48 hr after transfection with MAVS and start-site point-mutant expression vectors.
(B) Subsequent measurements were made at 30 and 48 hr after transfection to quantify the density of floating cells in the media. Transfection ofMAVS and the
start-site mutants were done in triplicate. Error bars represent SD.
(C) Detection of fragmented genomic DNA was performed 24 hr after transfection of various MAVS constructs and TRIF, and samples were separated on a 2%
agarose gel.
(D) Cell lysates were collected at 24, 30, and 48 hr post-transfection ofMAVS, the translational start point mutants, NLRX1, and TRIF. PARP cleavage and MAVS
expression were determined by immunoblot following SDS-PAGE.classes relative to the reading frame of the annotated CDS.
These include start sites for the canonical CDS, uORFs, internal
out-of-frame products, truncations, and extensions (Figure 6C).
Because our work with MAVS has highlighted the importance of
protein diversification via alternative translation, we focused our
analysis on transcripts with start sites that resulted in variant pro-tein isoforms such as truncations and extensions. These alterna-
tively translated products are of particular interest because they
can either lose or gain a functional domain relative to the canon-
ical CDS.MAVS is a clear example of this mode of regulation, as
the truncation miniMAVS lacks the CARD domain present in
the amino terminus of FL MAVS. In addition, our profiling dataCell 156, 800–811, February 13, 2014 ª2014 Elsevier Inc. 807
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Figure 6. Ribosomal Profiling of Human
Monocytes Identifies Extension and Trun-
cation Variants Similar to miniMAVS
(A) The fraction and number of genes that were
detected to have one or more translational start
sites.
(B) The fraction and number of genes that have
more than one translational start site resulting in
either an extension or truncation.
(C) Classification of each start site relative to the
reading frame of the annotated CDS.
(D) Venn diagram showing the number of genes
identified containing one or more canonical, trun-
cation, or internal out-of-frame start site.
(E) Venn diagram showing the number of genes
identified containing one or more canonical, trun-
cation, or extension start site.
See also Figure S3 and Table S2.indicate that truncations are more prevalent than would be
expected from random chance. Based on the use of triplet
codons, a third of possible start codons would be in-frame
with the canonical ORF and two-thirds would be out-of-frame.
If start-site selection were random, we would expect a 1:2 ratio
of truncations to internal out-of-frame ORFs. However, we
observed about a 4:3 ratio in the favor of truncations (Figure 6D).
Additionally, truncations appear to be more frequent than exten-
sions, suggesting that these variants may have more biological
significance (Figure 6E).
From the list of potential truncations, we chose several genes
involved in antiviral immunity to further investigate. The patterns
of ribosomal profiling indicate that, likeMAVS, IFIH1 (also known
as MDA-5), MX2, IFITM2, and TRIM25 might also encode for808 Cell 156, 800–811, February 13, 2014 ª2014 Elsevier Inc.truncated protein variants (Figures S3A–
S3D). However, other genes related
to antiviral immunity, such as DDX58
(RIG-I) and TMEM173 (STING), were not
identified as having truncations (Figures
S3E and S3F). Although additional work
is needed to verify the abundance and
function of these predicted protein vari-
ants, this analysis highlights the potential
existence of a class of bicistronic regula-
tors of antiviral innate immunity.
DISCUSSION
Regulation of innate immune signal trans-
duction is crucial for many aspects of cell
and organ physiology during infection
and homeostasis. Eukaryotes often regu-
late signaling pathways by producing
proteins with diverse function through
gene-extrinsic means (different genes
encoding different regulators) or gene-
intrinsic means (alternative splice variants
encoding different regulators). The use
of mRNA-intrinsic protein-diversificationstrategies (multiple translation products from the same tran-
script) has traditionally been characterized for prokaryotes and
viruses (Alberts, 2008; Powell, 2010). Our finding that MAVS
encodes a bicistronic mRNA that produces proteins with
different functions represents an unusual means by which pro-
tein diversity can be generated in the innate immune system.
Several lines of evidence support our conclusion that the
MAVS transcript is bicistronic. (1) The cDNA of MAVS can pro-
duce both FL MAVS and miniMAVS, and the molecular weight
of miniMAVS does not correspond to that of any possible prod-
uct of alternative splicing. (2) Profiling of ribosomes arrested at
translational start sites within the endogenous MAVS mRNA re-
vealed two start codons. These start codons are predicted to
produce proteins of the size corresponding to FL MAVS and
miniMAVS.When these start codons weremutated, the resulting
transcripts lost the ability to produce the corresponding MAVS
variant. (3) Shifting the reading frame of the MAVS coding
sequence at a site between these two start sites resulted in
the production of two distinct protein products (HA-shift and
miniMAVS). Because FLMAVS is not produced under these con-
ditions, the existence of miniMAVS cannot be explained by pro-
teolytic cleavage of the full-length protein. Collectively, the
above observations can only be explained by the conclusion
that FL MAVS and miniMAVS are produced from a bicistronic
mRNA encoded by the MAVS gene.
Our genome-wide ribosome-profiling analysis suggests that
FL MAVS and miniMAVS are not the only regulators of innate
immunity that are encoded by a bicistronic mRNA. Indeed,
this analysis revealed the existence of hundreds of transcripts
that are predicted to encode more than one protein product.
This result is consistent with prior work in embryonic stem cells
(Ingolia et al., 2011), which first suggested that polycistronic
mRNAs are prevalent in mammalian cells. Our analysis in
immune cells indicates that this feature of mammalian mRNAs
is not unique to stem cells. Rather, we suggest that polycistronic
mRNAs may be used to diversify protein function in differenti-
ated cells as well. Interestingly, our analysis suggests the exis-
tence of additional bicistronic regulators of antiviral immunity.
While much work needs to be done to verify the existence and
function of any predicted product of alternative translation, the
ability of ribosome-profiling approaches to predict the existence
of FL MAVS and miniMAVS strengthens confidence in these
analyses.
Our functional studies of miniMAVS revealed that FL MAVS
and miniMAVS antagonize one another, and that the strength
of antiviral gene expression induced by MAVS is the result of
the collective actions of these two MAVS variants. We suggest
that a competition exists within cells at the level of the MAVS
proteins, and the relative abundance of each variant may
determine the signaling potential of the RLR pathway. Mecha-
nistically, this competition may be occurring at the level of inter-
actions with downstream TRAF proteins. Evidence in support
of this suggestion comes from our studies indicating that
miniMAVS, like its full-length counterpart (Hou et al., 2011; Liu
et al., 2013), can form a complex with TRAF2 and TRAF6. It
will be important to further characterize the means by which
TRAFs can be recruited into functionally distinct protein com-
plexes consisting of either FL MAVS or miniMAVS. Interestingly,
in our attempts to understand the inhibitory role that miniMAVS
plays during IFN production, we noted that results were less reli-
able when the variants were expressed in trans. Whether this in-
dicates a requirement for expression in cis or rather a limitation
of experimental design was not determined. It is interesting to
speculate that the expression of regulatory variants from bicis-
tronic transcripts may have evolved based on a requirement
for expression in cis.
Due to the importance of MAVS in controlling viral infections
(Kumar et al., 2006; Sun et al., 2006), one might have expected
that theMAVSmRNAwould have evolved to contain a highly effi-
cient translational start site. However, our analysis of cis-acting
sequences in the MAVS transcript revealed otherwise. The
nucleotides surrounding the FL MAVS start codon do not fitthe classic definition of a Kozak sequence (Kozak, 1986, 1987),
and FL MAVS translation appears to be limited by the actions
of a uORF that overlaps with the start codon of FL MAVS. There-
fore, uORF-mediated start-codon skipping, a mode of regulation
previously found to maintain the polycistronic nature of the
mRNA encoding the transcription factor C/EBP (Calkhoven
et al., 2000; Raught et al., 1996), may facilitate the expression
of miniMAVS. We suggest that (in advanced mammalian spe-
cies) the endogenous 50 UTR of the MAVS transcript evolved
not to maximize the translation of FL MAVS but rather to balance
the production of FL MAVS with the production of its down-
stream miniMAVS partner.
Based on these data, we suggest that the gene encoding FL
MAVS and miniMAVS is functionally analogous to a bacterial
operon, in whichmultiple proteins can be produced from a single
mRNA and collectively control a cellular activity. The fact that FL
MAVS and miniMAVS participate in both the antiviral and cell-
death responses of human cells suggests that this mammalian
operon may be particularly important in maintaining tissue
homeostasis before, during, and after infections. These discov-
eries provide a mandate to consider the functions of additional
polycistronic regulators of innate immunity and indicate that
even ‘‘well-characterized’’ genes have much to reveal in terms
of their functions in health and disease.
EXPERIMENTAL PROCEDURES
Cloning and Generation of MAVS Mutants
TheMAVS CDS from allele BC044952 was a gift of Z.J. Chen (UTSW). Variants
were cloned into a pcDNA3 vector containing an N-terminal HA tag. Variants
were cloned with (strong translational context) or without (weak translational
context) the N-terminal tag. Both used the same C-terminal restriction site
XhoI, primer AAAAACTCGAGCTAGTGCAGACGCCGCCGGTACAGC. The
strong translational context variants were inserted into the vector with KpnI,
fwd primer AAAAAGGTACCGCACCGTTTGCTGAAGACAAGACCTAT. The
translational context at the HA start codon of this vector was as follows:
AAGCTTACGATGG. The weak translational context variants were inserted
with HindIII, which removed the HA tag, fwd primer TTTTTAAGCTTATGCC
GTTTGCTGAAGACAAGACCTAT. The translational context at the start codon
of this vector was as follows: CCCAAGCTTATGC. For the Kozak and anti-
Kozak constructs, the following sequences were placed directly upstream of
the FL MAVS start codon: GCCGCCACC and ATATATTTT. The sequence
used to generate the 50 UTR MAVS constructs is listed in the Ensemble data-
base under transcript ID number ENST00000428216. The HA-shift construct
was made by inserting two nucleotides ‘‘TA’’ at bp number 254 of the MAVS
CDS with the fwd primer GTGAGCTAGTTGATCTCGTACGGACGAAGTGG
CCTCTGTC. Stable MAVS cell lines were generated with pMSCV2.2 IRES
GFP in MAVS-deficient MEFs.
MAVS Expression, Antibodies, Type I IFN Bioassay, and Viral
Infections
MAVS in vitro expression was performed using a coupled transcription and
translation rabbit reticulocyte lysate kit (Promega) with a T7 pcDNA3 expres-
sion vector. MAVSwas expressed in 293T cells cultured in DMEM, 10% serum
by Fugene 6 (Promega) mediated transfection of pcDNA3 expression con-
structs. The antibodies used for western blots were MAVS (Bethyl Labs
A300-782A), pSTAT (BD 612132), PARP (BD 611038), HA (Roche 3F10), Flag
(Biolegend 637301) TRAF2 Cell Signaling (C192), and TRAF6 Abcam
(33915). The type I IFN bioassay was performed as previously described (Dixit
et al., 2010). Statistics were performed using PRISM (Graphpad). Cells were
infected with 50 U/ml of SeV or a multiplicity of infection (moi) = 1 for VSV firefly
luciferase. 33Flag-miniMAVS was immunoprecipitated with an M2-affinity gel
from Sigma and eluted with a FLAG peptide.Cell 156, 800–811, February 13, 2014 ª2014 Elsevier Inc. 809
Detection of DNA Fragmentation
Fragmented genomic DNA was observed by agarose gel electrophoresis
following phenol chlororform extraction (Matassov et al., 2004).
Detection of FL MAVS Oligomers by Sucrose Gradient
Ultracentrifugation
Sucrose gradient ultracentrifugation was performed as previously described
(Hou et al., 2011). Briefly, 5 3 105 293T cells were plated in 10 cm dishes
and transfected with MAVS expression vectors. Ten hours after transfection,
cells were lifted and lysed by dounce homogenization. A P5 crude mitochon-
drial pellet was obtained and solubilized in 1%DDM (Hou et al., 2011). Soluble
mitochondria were then loaded onto a 30%–60% sucrose gradient and centri-
fuged for 2 hr at 170,000 g 4C. Fractions were then removed from the gradient
with the bottom fraction containing MAVS oligomers.
Ribosomal Profiling
U937 cells were left untreated or treated for 5 min with 2 mg/ml of harringtonine
then immediately lysed. Ribosomal profiling and analysis were then carried out
as previously described (Ingolia et al., 2012).
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and two tables and can be
found with this article online at http://dx.doi.org/10.1016/j.cell.2014.01.021.
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